Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Research Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) on Bullrun: market cap HKD 45.69B, P/E 12.0, dividend yield 2.7%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2196.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 45.69B
- P/E12.0
- Dividend yield2.7%
- Financial periodQ1 2026
- RevenueCNY 10.07B
- Net incomeCNY 870.83M
- Free cash flowCNY 57.23M
- Gross margin49.7%
Valuation Snapshot
latest market cap is HKD 45.69B; P/E is 12.0; dividend yield is 2.7%.
Peer valuation comparison
Latest P/E is 11.97x versus a Healthcare sector median of 21.8x (45.1% below).
Latest dividend yield is 2.69% versus a Healthcare sector median of 2.4% (12.1% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 45.69B | 12.0 | 2.6% | 0.45 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.45 HKD, yield 2.7%.
About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others.
ETFs that hold Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
US-listed ETFs
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is held by 28 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | 0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Avantis Emerging Markets Equity ETF (AVEM) | <0.01% | 0.33% |
| Schwab Emerging Markets Equity ETF (SCHE) | 0.01% | 0.06% |
| Vanguard International High Dividend Yield Index Fund ETF Shares (VYMI) | 0.01% | 0.07% |
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s market cap?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s market capitalization is HKD 45.69B.
What is Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s P/E ratio?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s price-to-earnings (P/E) ratio is 12.0.
Does Shanghai Fosun Pharmaceutical (Group) Co., Ltd. pay a dividend?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has a dividend yield of 2.7%.
What does Shanghai Fosun Pharmaceutical (Group) Co., Ltd. do?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates.